Cardima Names Lawrence J. Siskind to Board of Directors; Adds Significant Intellectual Property, Registration and Trademark Expertise

Business Wire, Jan 8, 2002

Business Editors/Health & Medical Writers

FREMONT, Calif.--(BW HealthWire)--Jan. 8, 2002

Cardima(R), Inc. (Nasdaq:CRDM) -- developer of the REVELATION(TM) Tx and the REVELATION Helix(TM) microcatheter systems -- today announced the appointment of Lawrence J. Siskind (49) to the Company's Board of Directors. Mr. Siskind, a well-known and highly regarded attorney who served as a Special Counsel under both Presidents Ronald Reagan and George H. Bush, brings substantial domestic and international legal consulting expertise to Cardima's Board. His appointment brings the total number of Directors to five.

Currently in private practice at Harvey Siskind Jacobs LLP, a San Francisco intellectual property law firm, Mr. Siskind specializes in litigation, registration and transactional advice regarding domestic and international copyrights, trademarks, trade secrets and unfair competition. He has been lead counsel in a number of noteworthy First Amendment, trademark and copyright legal decisions. In 1987, President Reagan appointed Mr. Siskind as the nation's first Special Counsel for Immigration Related Unfair Employment Practices, a position he continued to hold under President Bush before returning to private practice in 1989. California Governor Pete Wilson appointed him to serve as a charter member of the State Commission on Academic Content and Performance Standards in 1996, and on the Electronic Commerce Advisory Counsel in 1998.

Mr. Siskind has written and lectured extensively on a number of legal topics. His articles have appeared in The Wall Street Journal, The Weekly Standard, The San Francisco Chronicle and The International Quarterly, among others. He graduated with high honors from Harvard College in 1974 and received his J.D. degree in 1978 from Harvard Law School, where he co-founded the Harvard Journal of Law and Public Policy.

"We are fortunate to have an individual of Larry's stature join our Board," said Gabriel Vegh, chief executive officer of Cardima. "His domestic and international legal expertise will be invaluable as we market the REVELATION Helix system in Europe, which recently received CE Mark approval, and seek approval for the REVELATION Tx System in the U.S. before the end of 2002."

Commenting on his Board appointment, Mr. Siskind said, "The REVELATION series of microcatheters are unique products that could improve the quality of life for people who suffer from atrial fibrillation. I'm pleased to be a part of this effort, and am enthusiastic about the potential success of the Company."

Cardima, Inc. developed its patented, unique series of REVELATION microcatheter systems for the mapping and treatment of atrial fibrillation (AF), which the Company believes is a potential $6 billion market that is poorly served by current treatment alternatives. AF afflicts an estimated 4.5 million people worldwide. The REVELATION series of microcatheters are minimally invasive, single-use microcatheters for potentially curing AF. Enrollment in a Phase III study for the Company's REVELATION Tx linear ablation microcatheter system is underway in the U.S. The Company is targeting U.S. approval for this device before the end of 2002. The Company's REVELATION Helix system received CE Mark approval in December 2001.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include the Company's ability to raise additional capital, conduct successful clinical trials, obtain regulatory approvals and gain acceptance from the marketplace for its products. Additional risks are set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2000 and Quarterly Reports on Form 10-Q for the quarters ended March 31, June 30 and September 30, 2001 filed with the Securities and Exchange Commission on March 22, May 14, August 14, 2001 and November 14, 2001, respectively. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.